Quinoline Derivative Control Agent for Mesostigmata Mite Resistance

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current control agents are ineffective against Mesostigmata mites that parasitize or suck blood from homoiotherms, with recent decreases in drug sensitivity necessitating a novel and highly effective agent.

Innovation Solution

Compounds such as azoxystrobin, picoxystrobin, and their acid addition salts are used as active ingredients in a Mesostigmata mite control agent, providing effective control against mites like red mites and northern fowl mites by direct application or to their habitats.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional control agents are used against Mesostigmata mites, then initial control effect is achieved, but drug sensitivity decreases over time rendering them ineffective

Engineering Contradiction:
Improvecontrol effectivenessVSAvoiddrug sensitivity duration
Core Design Contradiction:
ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies parameter changes by switching from conventional control agents to quinoline derivatives with specific chemical structures (formula 1). This chemical parameter change restores control effectiveness against Mesostigmata mites that have developed resistance to previous agents, thereby resolving the contradiction between initial effectiveness and long-term sensitivity maintenance

Inventive Principle:
Principle #35Parameter changes

2Reliability

If novel control agents are developed to overcome resistance, then control effectiveness is improved, but safety requirements become more stringent

Engineering Contradiction:
Improvecontrol effectivenessVSAvoidsafety profile
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing quinoline derivatives with specific substituent patterns (R1, R2, R3 groups in formula 1) that target Mesostigmata mite physiology specifically. This localized chemical design achieves high control effectiveness while maintaining safety by exploiting unique biological characteristics of the target mites rather than broad-spectrum toxicity

Inventive Principle:
Principle #3Local quality

Data Source

PatentUS12108761B2Mesostigmata mite control agent
Publication Date: 2024.10.08 MEIJI SEIKA KAISHA LTD
  • US12108761B2 patent drawing
  • US12108761B2 patent drawing
  • US12108761B2 patent drawing

AI summary

A control agent comprising, as an active ingredient, a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline, azoxystrobin, picoxystrobin, pyraclostrobin, kresoxim-methyl, trifloxystrobin, metominostrobin, orysastrobin, famoxadone, fluoxastrobin, pyribencarb, cyazofamid, amisulbrom, flutolanil, mepronil, isofetamid, fluopyram, carboxin, thifluzamide, fluxapyroxad, furametpyr, penflufen, penthiopyrad, boscalid, diflumetorim, fluazinam, ferimzone, fenpyroximate, or an acid addition salt of any of these compounds shows an excellent controlling effect on Mesostigmata mites.